Long‐Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis

BACKGROUND. Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (OS) of between 8 and 11 months. However, a significant number of patients experience a longer survival, more than 18 months. The aim of this study was to describe the “long‐ter...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Rochefort, Pauline, Lardy‐Cleaud, Audrey, Sarabi, Matthieu, Desseigne, Françoise, Cattey‐Javouhey, Anne, de la Fouchardière, Christelle
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2019
Ämnen:
Gastrointestinal Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6975934/
https://ncbi.nlm.nih.gov/pubmed/31164454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0786
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk